Comparison of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic non-toxic goitre

The efficacy of treatment with TSH-suppressive doses of L-thyroxine (T4, 2·5 μg/kg body weight daily) either alone or combined with carbimazole (CBZ, 40 mg daily) was studied in 78 patients with sporadic non-toxic goitre in a prospective placebo-controlled double-blind randomised clinical trial. Treatment was given for 9 months, with 9 months of follow-up. A response to treatment as measured by ultrasonography was found in 58% of the T4 group,...